| 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative F Van Den Hoogen, D Khanna, J Fransen, SR Johnson, M Baron, ... Arthritis & Rheumatism 65 (11), 2737-2747, 2013 | 5172 | 2013 |
| 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus M Aringer, K Costenbader, D Daikh, R Brinks, M Mosca, ... Arthritis & rheumatology 71 (9), 1400-1412, 2019 | 2628 | 2019 |
| 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia D Khanna, JD Fitzgerald, PP Khanna, S Bae, MK Singh, T Neogi, ... Arthritis care & research 64 (10), 1431-1446, 2012 | 2524* | 2012 |
| 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid … JA Singh, DE Furst, A Bharat, JR Curtis, AF Kavanaugh, JM Kremer, ... Arthritis care & research 64 (5), 625-639, 2012 | 2231 | 2012 |
| Definitions and diagnosis of pulmonary hypertension MM Hoeper, HJ Bogaard, R Condliffe, R Frantz, D Khanna, M Kurzyna, ... Journal of the American College of Cardiology 62 (25S), D42-D50, 2013 | 2205 | 2013 |
| American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials DT Felson, JS Smolen, G Wells, B Zhang, LHD Van Tuyl, J Funovits, ... Arthritis & Rheumatism 63 (3), 573-586, 2011 | 1858 | 2011 |
| Systemic sclerosis CP Denton, D Khanna The Lancet 390 (10103), 1685-1699, 2017 | 1850 | 2017 |
| Update of EULAR recommendations for the treatment of systemic sclerosis O Kowal-Bielecka, J Fransen, J Avouac, M Becker, A Kulak, Y Allanore, ... Annals of the rheumatic diseases 76 (8), 1327-1339, 2017 | 1087 | 2017 |
| 2020 American College of Rheumatology guideline for the management of gout JD FitzGerald, N Dalbeth, T Mikuls, R Brignardello‐Petersen, G Guyatt, ... Arthritis & Rheumatology 72 (6), 879-895, 2020 | 955 | 2020 |
| Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial DP Tashkin, MD Roth, PJ Clements, DE Furst, D Khanna, EC Kleerup, ... The lancet Respiratory medicine 4 (9), 708-719, 2016 | 944 | 2016 |
| Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study JG Coghlan, CP Denton, E Grünig, D Bonderman, O Distler, D Khanna, ... Annals of the rheumatic diseases 73 (7), 1340-1349, 2014 | 868 | 2014 |
| Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial D Khanna, CP Denton, A Jahreis, JM van Laar, TM Frech, ME Anderson, ... The lancet 387 (10038), 2630-2640, 2016 | 646 | 2016 |
| Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease DP Tashkin, R Elashoff, PJ Clements, MD Roth, DE Furst, RM Silver, ... American journal of respiratory and critical care medicine 176 (10), 1026-1034, 2007 | 571 | 2007 |
| Distinctions between diagnostic and classification criteria? R Aggarwal, S Ringold, D Khanna, T Neogi, SR Johnson, A Miller, ... Arthritis care & research 67 (7), 891-897, 2015 | 546 | 2015 |
| Myeloablative autologous stem-cell transplantation for severe scleroderma KM Sullivan, EA Goldmuntz, L Keyes-Elstein, PA McSweeney, A Pinckney, ... New England Journal of Medicine 378 (1), 35-47, 2018 | 521 | 2018 |
| Recombinant human anti–transforming growth factor β1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo‐controlled phase I/II trial of CAT‐192 CP Denton, PA Merkel, DE Furst, D Khanna, P Emery, VM Hsu, N Silliman, ... Arthritis & Rheumatism 56 (1), 323-333, 2007 | 518 | 2007 |
| Natural products as a gold mine for arthritis treatment D Khanna, G Sethi, KS Ahn, MK Pandey, AB Kunnumakkara, B Sung, ... Current opinion in pharmacology 7 (3), 344-351, 2007 | 496 | 2007 |
| Diagnosis of pulmonary hypertension A Frost, D Badesch, JSR Gibbs, D Gopalan, D Khanna, A Manes, R Oudiz, ... European Respiratory Journal 53 (1), 2019 | 491 | 2019 |
| Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis D Khanna, DE Furst, PJ Clements, Y Allanore, M Baron, L Czirjak, ... Journal of scleroderma and related disorders 2 (1), 11-18, 2017 | 456 | 2017 |
| Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial D Khanna, CJF Lin, DE Furst, J Goldin, G Kim, M Kuwana, Y Allanore, ... The Lancet Respiratory Medicine 8 (10), 963-974, 2020 | 428 | 2020 |
Daniel E. FurstUCLA, Pacific Medical Clinic, Univ. of Washington, University of Florence, ItalyAdresse e-mail validée de furst.us.com
